Data from the DREAM 7 trial reveals that holding belantamab doses for 12 weeks or longer to manage ocular toxicity did not negatively impact progression-free survival (PFS). Responding patients often maintain their response, challenging the conventional wisdom that strict dosing schedules are paramount for efficacy.

Progress in drug development often hides inside failures. A therapy that fails in one clinical trial can provide critical scientific learnings. One company leveraged insights from a failed study to redesign a subsequent trial, which was successful and led to the drug's approval.

The DREAM-7 trial showed a belantumab combination had an overall survival benefit versus a daratumumab regimen, a "premier drug" that previously changed the myeloma treatment landscape. This surprising result establishes a new, higher standard of care and positions belantumab as a top-tier therapy, not merely another option.

For a small biotech, demonstrating that a drug is both clinically active on its own and well-tolerated is the most critical step. This de-risks the asset and opens the door to lucrative combination therapy partnerships with large pharma companies, as it minimizes the risk of combined toxicity killing the trial.

Belantamab's primary mechanism, immunogenic cell death, does not exhaust T-cells. This unique quality allows clinicians to use it as a first BCMA-targeted agent without compromising the efficacy of subsequent T-cell redirecting therapies like CAR T or bispecifics.

New oral CELMoDs like mezigdemide show a surprising ability to make previously ineffective drugs, like bortezomib and carfilzomib, work again. This resensitization mechanism offers a powerful strategy to recycle older therapies, expanding options for heavily pretreated patients.

Despite several monotherapies approaching approval for non-muscle invasive bladder cancer (NMIBC), the market is already shifting focus to combination therapies. RealMata's promising doublet data and CG Oncology's new combo trials signal that doublets will likely become the standard of care much faster than anticipated.

Unlike CAR T and bispecifics, the antibody-drug conjugate Belantamab doesn't rely on T-cell function. This makes it a strategic choice for patients who have previously received T-cell engaging therapies, allowing their T-cells to recover while still providing an effective BCMA-targeted treatment.

Clinicians report significant and durable responses using Belantamab in patients who have relapsed after BCMA-targeted CAR-T. This success may be due to Belantamab's immunogenic mechanism, which doesn't rely on endogenous T-cells and may favorably interact with the post-CAR immune environment.